Clinical trials: Pancreas Tumor
Pancreatic Cancer
Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
- Trial name
- NCT02345408
- Testing
- CCX872-B
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 54 people
- Sponsor
- Amgen
Autoimmune Pancreatitis, Pancreatic Ductal Adenocarcinoma (PDAC)
AI-Assisted Differentiation of Autoimmune Pancreatitis and Pancreatic Cancer Using EUS: A Multicenter Ambispective Study
Focal autoimmune pancreatitis (f-AIP) and pancreatic ductal adenocarcinoma (PDAC) exhibit substantial overlap in clinical manifestations and imaging features, posing a major diagnostic challenge in pancreatic diseases.
- Trial name
- NCT07900776
- Volunteers
- 690 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer, Chemotherapy Effect
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor, even in those patients who had underwent surgery, the 5-year survival is still less than 10%.
- Trial name
- GCRP (NCT03498326)
- Testing
- Gemcitabine
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
IRE
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with locally advanced pancreatic cancer who have received three cycles of chemotherapy induction and have…
- Trial name
- NCT07799935
- Testing
- IRE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- ACTION-1 (NCT05477576)
- Testing
- RYZ101, Everolimus, Sunitinib
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- RayzeBio, Inc.
Lung Cancer, Breast Cancer
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced…
- Conditions
- Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- NCT00096707
- Testing
- 2-deoxy-D-glucose (2DG)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Threshold Pharmaceuticals
Pancreatic Adenocarcinoma
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic…
- Trial name
- NCT04983407
- Testing
- batiraxcept, Nab paclitaxel, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aravive, Inc.
Pancreatic Cancer, Resectable Carcinoma
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer.
- Trial name
- MAP-02 (NCT05802407)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Cancer, Pancreatic Cancer
Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00436267
- Testing
- fluorouracil, selective external radiation therapy, tomotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Goshen Health System
Pancreatic Neoplasms, Pancreatitis
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
"Snapshot" study worldwide over 3 months in 2021. Provide a verified record of true morbidity and mortality. Identify modifiable predicting factors of outcome. Obtain PubMed citable co-authorship,
- Trial name
- NCT04652271
- Testing
- Pancreatic surgery
- Volunteers
- 3,500 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Pancreatic Cancer
Immune Response After Pancreatic Cancer Treatment
The aim of this project is to describe the differential immunologic responses of patients who undergo in situ IRE, margin accentuation IRE with surgical resection of the primary tumor, and surgical resection of the primary tumor…
- Trial name
- IRE Immuno (NCT03069599)
- Testing
- irreversible electroporation (IRE)
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Advanced Pancreatic Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced pancreatic cancer.
- Trial name
- NCT03509298
- Testing
- Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer, cryotherapy
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
This study is the study of the combination of PEGPH20 and Pembrolizumab (MK-3475) for patients with previously treated Hyaluronan High (HA-high) metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- NCT03634332
- Testing
- PEGPH20, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Cancer
Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
The purpose of this study is to investigate the effect of very low dose decitabine combinate with gemcitabine in the first-line treatment of locally advanced, unresectable and metastatic pancreatic cancer.
- Trial name
- SLOWDOSE001 (NCT02685228)
- Testing
- Decitabine, Gemcitabine
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pancreatic Neoplasms
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that…
- Trial name
- CKPancreas (NCT03199144)
- Testing
- Chemotherapy, Stereotactic radiotherapy, Surgery
- Where
- Luxembourg
- Sponsor
- Centre Francois Baclesse, Luxembourg
Breast Cancer, Colorectal Cancer
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor…
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00002475
- Testing
- allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Vincent Medical Center - Los Angeles
Pancreatic Neoplasms, Pancreatitis, Chronic
Magnetic Compressive Technique for Pancreatic Intestinal Anastomosis
In recent five years, the investigators have successfully developed different types of magnets and utilized in biliojejunostomy, concomitant biliojejunostomy and pancreaticojejunostomy during Whipple.
- Trial name
- MCTPIA (NCT03780946)
- Testing
- Magnetic anastomosis for pancreaticojejunostomy, Traditional hand-sewn anastomosis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepato-Biliary Carcinoma in Situ Nos, Pancreatic Cancer
Assessing the Accuracy of Seismofit® as an Estimate of VO2 Peak in Patients With Hepato-pancreato-biliary, Colorectal, and Gastro-oesophageal Cancer
Our study aims to assess the relationship between the Seismofit® derived VO2 peak estimate and CPET-measured VO2 peak in patients who are having CPET as part of their preoperative workup.
- Conditions
- Hepato-Biliary Carcinoma in Situ Nos, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- VERVE (NCT05831488)
- Testing
- Non-Interventional
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Royal Marsden NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.